Operator

Good morning, and welcome to the Novacyt Full Year Results Investor Presentation. [Operator Instructions] Before we begin, I would like to submit the following poll.

I would now like to hand you over to CEO, Lyn Rees. Good morning to you.

Lyn Rees
CEO & Executive Director

Good morning, Alex, and thank you. And good morning to all of our investors as well. I understand there's potentially up to 150 people joining us online this morning. So as ever, we thank you for your time and your commitment this morning.

I'm joined today by Steve Gibson, our CFO. So between myself and Steve, we'll be going through the results presentation. And this represents, pretty much, our second year anniversary as the CEO and CFO of this organization. So really looking forward to updating on what I think has been some really solid progress over the last 12 months for this business.

I'm just going to start with a quick introduction slide of what we do. I mean, what we do, sorry. Obviously, a lot of people will realize that we're an international molecular diagnostics company with a portfolio of clinical assays. That's the Yourgene Health side of the diagram. We have a series of research tools and instrumentation that are done on a research use-only basis. That's the Primer Design side of this diagram. And then in the middle there, you'll see a brand-new part of our business, the distributor part of our business as a result of the acquisition of Southern Cross Diagnostics. And we'll be talking a little bit about that as we go through this deck, okay?